FIGURE 4.

Effect of KD1-WT, KD1-L17R, BPTI, and TE on fibrinolysis in human NPP. A, evaluation of fibrinolysis in NPP. IIa was added to NPP to initiate fibrin clot formation, which is associated with an increase in optical density at 405 nm (OD₄₀₅). The clot was stable for 4 h; however, for clarity, the data are shown for up to 30 min only (▴). Simultaneously added tPA converted plasminogen to Pm, which dissolved the fibrin clot completely within ∼12 min, as indicated by an initial increase followed by a decrease in OD₄₀₅ (Δ). Addition of KD1-L17R inhibited fibrinolysis in a dose-dependent manner as follows: 0.5 μm (●), 1 μm (○), 2 μm (■), and 4 μm (□), respectively. For comparison, such data were collected for all four antifibrinolytic compounds at varying concentrations, and fibrinolysis was evaluated as the % lysis (decrease in OD₄₀₅) at 12 min, the time at which the fibrin clot is completely lysed without the added inhibitor. B, evaluation of the potency of various antifibrinolytic agents. BPTI was tested at concentrations ranging from 0.01 to 8 μm, KD1-L17R from 0.1 to 20 μm, KD1-WT from 0.1 to 60 μm, and TE from 0.3 to 1000 μm. The data are presented as average of three determinations. Percent clot lysis (y axis) at 12 min is plotted against inhibitor concentration (x axis, log scale). BPTI, Δ; KD1-L17R, ●; KD1-WT, ○; and TE, ▴.